Trial Profile
Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) Standard Injection in Tumor Treatment Scheme Failed M1c Ⅳ Period Malignant Melanoma Spread to the Liver Open I-c Phase of Clinical Trial
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs OrienX 010 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors OrienGene Biotechnology
- 06 Jun 2017 Results (n=15) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 14 Feb 2017 New trial record